PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
HCAT vs. AVAH
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between HCAT and AVAH is 0.30, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.3

Performance

HCAT vs. AVAH - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Health Catalyst, Inc. (HCAT) and Aveanna Healthcare Holdings Inc. (AVAH). The values are adjusted to include any dividend payments, if applicable.

-20.00%-10.00%0.00%10.00%20.00%30.00%SeptemberOctoberNovemberDecember2025February
-22.33%
-7.14%
HCAT
AVAH

Key characteristics

Sharpe Ratio

HCAT:

-0.65

AVAH:

1.32

Sortino Ratio

HCAT:

-0.83

AVAH:

2.26

Omega Ratio

HCAT:

0.90

AVAH:

1.27

Calmar Ratio

HCAT:

-0.49

AVAH:

1.22

Martin Ratio

HCAT:

-1.54

AVAH:

8.03

Ulcer Index

HCAT:

28.95%

AVAH:

12.61%

Daily Std Dev

HCAT:

69.19%

AVAH:

76.63%

Max Drawdown

HCAT:

-90.79%

AVAH:

-94.76%

Current Drawdown

HCAT:

-90.54%

AVAH:

-61.13%

Fundamentals

Market Cap

HCAT:

$337.70M

AVAH:

$968.06M

EPS

HCAT:

-$1.34

AVAH:

-$0.35

Total Revenue (TTM)

HCAT:

$226.98M

AVAH:

$1.50B

Gross Profit (TTM)

HCAT:

$85.54M

AVAH:

$458.08M

EBITDA (TTM)

HCAT:

-$15.03M

AVAH:

$105.60M

Returns By Period

In the year-to-date period, HCAT achieves a -21.50% return, which is significantly lower than AVAH's 9.63% return.


HCAT

YTD

-21.50%

1M

1.09%

6M

-22.38%

1Y

-42.84%

5Y*

-28.79%

10Y*

N/A

AVAH

YTD

9.63%

1M

7.74%

6M

-7.14%

1Y

119.74%

5Y*

N/A

10Y*

N/A

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

HCAT vs. AVAH — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

HCAT
The Risk-Adjusted Performance Rank of HCAT is 1313
Overall Rank
The Sharpe Ratio Rank of HCAT is 1414
Sharpe Ratio Rank
The Sortino Ratio Rank of HCAT is 1313
Sortino Ratio Rank
The Omega Ratio Rank of HCAT is 1515
Omega Ratio Rank
The Calmar Ratio Rank of HCAT is 1717
Calmar Ratio Rank
The Martin Ratio Rank of HCAT is 44
Martin Ratio Rank

AVAH
The Risk-Adjusted Performance Rank of AVAH is 8383
Overall Rank
The Sharpe Ratio Rank of AVAH is 8383
Sharpe Ratio Rank
The Sortino Ratio Rank of AVAH is 8383
Sortino Ratio Rank
The Omega Ratio Rank of AVAH is 7979
Omega Ratio Rank
The Calmar Ratio Rank of AVAH is 8282
Calmar Ratio Rank
The Martin Ratio Rank of AVAH is 8888
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

HCAT vs. AVAH - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Health Catalyst, Inc. (HCAT) and Aveanna Healthcare Holdings Inc. (AVAH). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for HCAT, currently valued at -0.65, compared to the broader market-2.000.002.00-0.651.32
The chart of Sortino ratio for HCAT, currently valued at -0.83, compared to the broader market-4.00-2.000.002.004.006.00-0.832.26
The chart of Omega ratio for HCAT, currently valued at 0.90, compared to the broader market0.501.001.502.000.901.27
The chart of Calmar ratio for HCAT, currently valued at -0.49, compared to the broader market0.002.004.006.00-0.491.22
The chart of Martin ratio for HCAT, currently valued at -1.54, compared to the broader market0.0010.0020.0030.00-1.548.03
HCAT
AVAH

The current HCAT Sharpe Ratio is -0.65, which is lower than the AVAH Sharpe Ratio of 1.32. The chart below compares the historical Sharpe Ratios of HCAT and AVAH, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.004.00SeptemberOctoberNovemberDecember2025February
-0.65
1.32
HCAT
AVAH

Dividends

HCAT vs. AVAH - Dividend Comparison

Neither HCAT nor AVAH has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

HCAT vs. AVAH - Drawdown Comparison

The maximum HCAT drawdown since its inception was -90.79%, roughly equal to the maximum AVAH drawdown of -94.76%. Use the drawdown chart below to compare losses from any high point for HCAT and AVAH. For additional features, visit the drawdowns tool.


-90.00%-80.00%-70.00%-60.00%-50.00%SeptemberOctoberNovemberDecember2025February
-90.54%
-61.13%
HCAT
AVAH

Volatility

HCAT vs. AVAH - Volatility Comparison

The current volatility for Health Catalyst, Inc. (HCAT) is 14.01%, while Aveanna Healthcare Holdings Inc. (AVAH) has a volatility of 15.90%. This indicates that HCAT experiences smaller price fluctuations and is considered to be less risky than AVAH based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


10.00%20.00%30.00%40.00%SeptemberOctoberNovemberDecember2025February
14.01%
15.90%
HCAT
AVAH

Financials

HCAT vs. AVAH - Financials Comparison

This section allows you to compare key financial metrics between Health Catalyst, Inc. and Aveanna Healthcare Holdings Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab